Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coherex clinches $8.5m to develop PFO (patent foramen ovale) closure device:

This article was originally published in Clinica

Executive Summary

Coherex Medical has closed a $8.5m series A financing round led by Oxford Bioscience and vSpring Capital. Salt Lake City, Utah-based Coherex intends to use the funds to drive development of its FlatStent patent foramen ovale (PFO) closure system and for general corporate purposes. A PFO is an abnormal opening between the upper chambers of the heart that could lead to stroke or cause migraines among those that have this defect. PFO-related stroke represents a worldwide market of around $2bn, while the global market for PFO closure to treat migraine patients is estimated to be over $15bn, says Coherex.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT048135

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel